Short Report

During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study



Journal of Psychopharmacology 0(00) 1–8 © The Author(s) 2009 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881109348165 jop.sagepub.com



Derek G Moore¹, John D Turner¹, Andrew C Parrott², Julia E Goodwin¹, Sarah E Fulton³, Meeyoung O Min³, Helen C Fox⁴, Fleur MB Braddick¹, Emma L Axelsson¹, Stephanie Lynch¹, Helena Ribeiro¹, Caroline J Frostick¹ and Lynn T Singer³

Abstract

While recreational drug use in UK women is prevalent, to date there is little prospective data on patterns of drug use in recreational drug-using women immediately before and during pregnancy. A total of 121 participants from a wide range of backgrounds were recruited to take part in the longitudinal Development and Infancy Study (DAISY) study of prenatal drug use and outcomes. Eighty-six of the women were interviewed prospectively while pregnant and/or soon after their infant was born. Participants reported on use immediately before and during pregnancy and on use over their lifetime. Levels of lifetime drug use of the women recruited were high, with women reporting having used at least four different illegal drugs over their lifetime. Most users of cocaine, 3,4-methylenedioxy-N-methylamphetamine (MDMA) and other stimulants stopped using these by the second trimester and levels of use were low. However, in pregnancy, 64% of the sample continued to use alcohol, 46% tobacco and 48% cannabis. While the level of alcohol use reduced substantially, average tobacco and cannabis levels tended to be sustained at pre-pregnancy levels even into the third trimester (50 cigarettes and/or 11 joints per week). In sum, while the use of 'party drugs' and alcohol seems to reduce, levels of tobacco and cannabis use are likely to be sustained throughout pregnancy. The data provide polydrug profiles that can form the basis for the development of more realistic animal models.

Keyword

MDMA, ecstasy, cannabis, alcohol, tobacco, cocaine, amphetamines, Recreational drugs, Party drugs, drug use, Polydrug use, Pregnancy, Humans, Prenatal exposure, in utero, women, mothers, fetal exposure, maternal life style, DAISY

Introduction

In the UK the majority of young men and women drink alcohol and, despite health campaigns, rates of tobacco smoking remain high. The use of so-called recreational drugs is also commonplace and is not restricted to low socio-economic status (SES) groups, with the use of cannabis and other 'party' drugs, such as ecstasy, cocaine and amphetamines, highly prevalent among young adults from all backgrounds. According to the British Crime Survey, 24% of the 16- to 24-year-old age group in England and Wales report having used one or more illicit substances in the last year (Nicolas et al., 2007). Whilst males are more likely to use illicit substances than women, recent UK and EU data show that this gender gap is narrowing and that the experiences and drug use patterns of younger men and women are increasingly similar (EMCDDA, 2005).

Although there are considerable data and publicity on the impact on the unborn child of 'harder' drug use by dependent

users of cocaine and heroin, and increasing publicity on the impact of alcohol and smoking, young, non-dependent, recreational drug-using women receive little direct information on the specific effects of recreational 'party' drugs in pregnancy, and particularly the potential impact of combining these drugs. This lack of information could potentially lead to the belief that some recreational drugs are less harmful

³Case Western Reserve University, Cleveland, OH, USA.

⁴Yale University, New Haven, CT, USA.

Corresponding author:

¹University of East London, London, UK.

²University of Swansea, Swansea, UK.

Derek Moore, Institute for Research in Child Development, School of Psychology, University of East London, Stratford Campus, Water Lane Stratford, London, E15 4NO, UK. Tel: +44 208 223 4433. Email: d.g.moore@uel.ac.uk

than others and could be responsible for their continued use during pregnancy.

One first step in addressing these issues is to establish the likely combinations and levels of 'party' drug use that will be taken during pregnancy by women who are self-confessed recreational drug users, and to use this information to model the effects. If we are to begin to address this issue in the UK we need more detailed prospective longitudinal data on the patterns of drug use of UK drug-using women before, during and after pregnancy, and in particular, information on the likely levels and combinations of infant drug exposure. In addition, in order to assess the impact on the developing foetus, we need to have details on how levels of use are likely to change across trimesters.

This paper presents one of the first detailed prospective reports of polydrug recreational drug use by a cohort of pregnant self-acknowledged recreational drug-using women in the UK. These women took part in the Development and Infancy Study (DAISY) study and were interviewed about their lifetime use, and their use in pregnancy of all common 'party' drugs, but particularly their use of cannabis and ecstasy (3,4methylenedioxy-N-methylamphetamine, (MDMA)). MDMA and cannabis are among the most widely-used illicit recreational drugs in young adults in the UK and are often taken together and in conjunction with other psychoactive substances (DAWN, 2000; Johnston et al., 2001; Parrott, 2004, 2006; Scholey et al., 2004; Singer et al., 2004a; Yacoubian et al., 2003). Cannabis is of particular interest as it is a drug that young (non-pregnant) women appear to consider to be less harmful than other illicit drugs (Pearson and Shiner, 2002) and prevalence in the general population of pregnant women in the UK has been reported to be around five in 100 (Fergusson et al., 2002).

Many studies have concluded that MDMA and cannabis are associated with psychobiological problems in adult users (e.g. Milani et al., 2000; Parrott et al., 2001; Rodgers, 2000). These adult neuro-psychobiological effects are likely to have important influences upon the behaviour of young women who are pregnant and, if use is continued throughout and beyond pregnancy, may have a significant impact on their ability to care for their children once born. While there are some mixed reports on its impact on daily living, MDMA use has been shown to be associated with poorer general psychological health (Parrott et al., 2000, 2001; Thomasius et al., 2006), specifically with depression (de Win et al., 2004; MacInnes et al., 2001; Lamers et al., 2006) and increased anxiety (Lamers et al., 2006). MDMA use has also been found to be associated with impairments in prospective memory and in social and emotional intelligence (Reay et al., 2006; Rendell et al., 2007). While these effects may not have an undue impact on the daily living of non-parents, these combined effects could impact significantly on a mother's capacity for caring for and relating to her children. There are also likely to be direct effects on the developing infant, with growing evidence of the long-term effects on the physical and psychological health of children of the use of cannabis and cocaine (Fried and Smith, 2001; Hingson et al., 1982; Huizink and Mulder, 2006; Singer et al., 2004b).

In the case of MDMA, while there is a growing literature on its effects in utero and post-partum on animals (for reviews, see Piper, 2007; Skelton et al., 2008), there is very little data available on the specific impact of this drug on human infants to date (McElhatton et al., 2004) and no data on its neuropsychological impact on human infants. Further, and the focus of this paper, little is known about the likely levels of use in pregnancy of MDMA by recreational drug-using women. We need more information on the likely levels of use of individual 'party' drugs by pregnant, recreational drug-using women, and also the likely extent of multiple or 'polydrug' use, and information on patterns of continued use (Havens et al., 2009). This information will allow the development of better animal models of the impact of drugs on the unborn child. In this first paper from the DAISY study, we present longitudinal prospective data on the levels and patterns of polydrug use before and during pregnancy in a cohort of self-identified recreational drug-using women from the UK.

Method

Participants

Within the UK health system the point at which non-dependent drug use is routinely raised with pregnant mothers is at the initial booking appointment with a midwife. While we initially attempted to recruit participants via midwives and by distributing leaflets to antenatal clinics, we found that this method of recruitment was relatively unsuccessful. The best recruitment method proved to be through paid adverts in pregnancy magazines. These asked to hear from pregnant women who 'used recreational drugs at some point during their pregnancy, even if it was before you knew you were pregnant'. The leaflets and adverts explicitly listed ecstasy, tobacco, cannabis, alcohol and cocaine as examples of recreational drugs. The participants were, therefore, a sample of women who identified themselves as recreational drug users and who were interested, or potentially concerned, about the effects of drugs on their developing babies. To encourage candour, participants were informed that their data would not be released to health professionals. All participants gave informed written consent under procedures approved by the university and National Health Service (NHS) ethics committees.

In the course of five years, 121 women contacted the study. Of these, 11 did not respond to further contact, four had miscarriages, two withdrew because their partner objected to their participation, one withdrew because of mental health problems, four lived or moved too far away for interviewers to visit, one did not meet the criteria, in two cases the child was too old and four participants withdrew for an unspecified reason. Of the remaining 92 women, four mothers provided data on pregnancy use, but at submission of this paper had not provided data on lifetime use, and two women used no drugs, alcohol or tobacco in their lifetime or in pregnancy. As this paper is concerned with patterns of drug use in lifetime and during pregnancy for known recreational drug users, we have not included their data here.

This left a cohort of 86 women who provided interview data about lifetime drug use and drug use during pregnancy. Sixty-six (75.7%) of these 86 women were recruited through paid adverts in pregnancy magazines, eight (9.3%) were

recruited through hospital antenatal clinics and physicians (general practitioners (GPs)), three (3.5%) through drug agency magazines, websites and flyers in bars and music venues, two (2.3%) through adverts in shops, libraries and student unions and seven (8.1%) were through word of mouth and other routes. The participants were recruited from a wide geographical area across the UK.

A strength of the sample was that the women recruited were not predominantly from low SES backgrounds and they spanned a range of occupational and educational groupings with a range of household incomes (see Table 1). The relationship circumstances of the women varied with 14 women single, 44 unmarried and cohabiting, 27 married and cohabiting and one undisclosed. The mean age of the women was 30.3 years. The women were from a representative range of ethnic groups.

Table 1. Characteristics of the sample

		N = 86
Maternal age at birth of child	Mean	30.3
	SD	6.3
	Range	18.5-43.5
		n (%)
Maternal social economic status	Professional/managerial	25 (29.1%)
	Intermediate	15 (17.4%)
	Routine/manual	9 (10.5%)
	Unemployed/full-time mother	33 (38.4%)
	No classification	4 (4.7%)
Marital status	Married	27 (31.4%)
	With partner	44 (51.2%)
	Single	14 (16.3%)
	Other	1 (1.2%)
Maternal ethnic origin	Asian/Indian	4 (4.7%)
	Black	7 (8.1%)
	Mixed race	4 (4.7%)
	White European	71 (82.6%)
Maternal qualifications	Degree	28 (32.6%)
	Vocational qualification	27 (31.4%)
	A Levels	10 (11.6%)
	GCSEs	13 (15.1%)
	No formal qualification	7 (8.1%)
	Other	1 (1.2%)
Household income	<£10,000	14 (16.3%)
	£10-20,000	19 (22.1%)
	£20-30,000	18 (20.9%)
	£30-40,000	13 (15.1%)
	>£40,000	21 (24.4%)
	Undisclosed	1 (1.2%)

GCSEs: UK age 16 school-leaving qualifications; vocational: school or post-school semi-skilled vocational training; A levels: UK advanced, age 18, school/college qualification; degree: bachelors level or above UK university degree qualification.

Drug interviews

Once recruited into the study, trained researchers visited the women at home, interviewed them in a private room at the university, or, in a small number of cases, interviewed them by phone. The interview schedule was an adaptation of the Maternal Post-Partum Interview (Singer et al., 2002). The interview was adapted to ask about substances commonly used in UK cohorts based on our own previously used drug questionnaires (Milani et al., 2005). The interview consisted of three parts: Lifetime, P1 and P2.

The first part (Lifetime) asked about lifetime drug use and use in the year leading up to conception. Depending on the extent of drug use, this part took around 45 minutes to complete. Where mothers were recruited into the study early in pregnancy this was administered as soon as possible, but in some cases, because of time constraints, this part was deferred to post-partum in order to prioritize the collection of the pregnancy data. Fifty-seven participants completed the lifetime interview during pregnancy with 79 having completed it by four months post-partum.

The second part of the interview (P1) asked about drug use in the month prior to pregnancy and over the first two trimesters and took around 30 minutes to complete. For mothers recruited early in pregnancy, this was administered at the end of the second trimester. Fifty-four participants completed P1 during pregnancy with 80 completing it by four months postpartum.

The third section (P2) asked about drug use during the final trimester, taking up to 30 minutes to complete. The intention was to administer this at one month post-partum (or if feasible just prior to birth). For women recruited in the latter stages of pregnancy, data were collected after the birth. Seven women completed P2 during pregnancy with a further 61 completing this at one month post-partum as planned and 81 women completing it by nine months post-partum.

Thus, the pattern of administration of the parts varied depending on the circumstances and timing of recruitment and the time available: where the participant was recruited during mid-pregnancy we combined the Life and P1 sections; for women recruited late in pregnancy we concentrated on completing the P1 and P2 sections and deferred the Lifetime section to a later date. It was not practical to complete all three sections in one session. All participants except one¹ completed all three parts of the interview.

For each section of the interview, values were reported/ computed for number/amount of tobacco cigarettes, units of alcohol, cannabis smoked or ingested, tablets of ecstasy taken, cocaine lines snorted and/or grams, crack/cocaine rocks, amphetamine wraps and tablets, heroin smoked or injected, ketamine snorted or injected, benzodiazepine tablets, d-Lysergic Acid Diethylamide (LSD) and hallucinogenic mushrooms. The interview also allowed for reporting of other substances and/or alternative methods of administration. For each drug, the frequency of use was recorded on a scale ranging from 0 (not at all) to 7 (daily use). By utilising frequency data, and the reported usual amounts of each drug

¹One woman provided lifetime and P1 data but no P2 data.

taken on a typical occasion, we calculated the average dose per week for each of the six drug-use periods reported below.

Drug Abuse Screening Test (DAST)

We also administered the DAST to explore whether our sample consisted of 'recreational' users who had significant drug abuse problems. The DAST is a 20-item scale validated against the DSM-III and yields a quantitative index of the degree of problems related to drug use and misuse (Gavin et al., 1989). A score of 16 out of 20 or above indicates a severe level of drug problems.

Results

Eighty-one of the 86 participants completed the DAST interview. Although some of our sample were using opiates, only three women scored greater than the cut off of 16 with a DAST score MEAN = 5.48 and SD = 4.4.

Lifetime use and use in the year before pregnancy

The first data we examined was the level of reported drug usage in the sample over their lifetime and in the year immediately prior to pregnancy. This subsequently allowed baseline levels of use to be compared with usage during pregnancy. Table 2 shows the number of the 86 participants who reported using each drug during their lifetime and pregnancy and the average levels of use at each period in time for those who used each drug. This included a sub-sample of 13 participants who used alcohol and tobacco, but no illicit drugs in their lifetime, and a small sub-sample of users who had used opiates and crack but who did not consider themselves to be dependent users.

Alcohol was the most frequently used drug in lifetime with all 86 women having used this in their lifetime, with 83 of the 86 using it in the year immediately before pregnancy. Tobacco and cannabis were also widely used in lifetime (tobacco lifetime n = 73, year before n = 63; cannabis lifetime n = 68, year before n = 53). The two next most widely used drugs in the year prior to pregnancy were MDMA and powder cocaine (MDMA lifetime n = 54, year before n = 32; powder cocaine lifetime n = 56, year before n = 30). Levels of usage of alcohol, tobacco, cannabis and other stimulants prior to pregnancy were similar to those reported in previous studies of non-pregnant drug-using women (Milani et al., 2004).

Lifetime use of amphetamines was reported by 55 women, although only 12 had used it in the year leading up to pregnancy. Ketamine, LSD, opiates, 'magic mushrooms', crack-cocaine and tranquilizers showed a similar pattern to amphetamines with number of users reducing considerably between lifetime and the year prior to pregnancy.

Profiles of polydrug use

An issue of interest for modelling the effects of drugs is knowing what polydrug combinations are most prevalent, that is to what extent those who used one drug also used other drugs. There was considerable polydrug use in the sample. Not counting alcohol and tobacco, one participant reported having used ten recreational drugs in her lifetime, 16 participants had used eight or more drugs, nine had used seven drugs, 14 had used six drugs, 11 had used five drugs and 23 had used between one and four drugs. The mean number of different drugs reported in the lifetime for the whole sample was 4.55 (SD = 2.99). Table 3 shows the extent to which there was overlap across each drug combination during lifetime, the year before and in the first trimester. In the year before pregnancy the number of participants using illicit drugs was fewer, with 24 participants reporting using no illicit drugs during this period, 21 participants reported using one illicit drug, 36 participants used two to four drugs and seven reported using five to eight drugs.

Change in use over the three trimesters

To explore the profile of reduction across trimesters we examined the numbers of participants who continued to use

Table 2. Average reported drug use per week for those women using the drug over their lifetime, the year before and the month before pregnancy, and during each of the three trimesters

		Lifetime		Year before		Month before		1 st trimester		2 nd trimester		3 rd trimester						
Total N=86	n	Mean	SD	n	Mean	SD	n	Mean	SD	n	Mean	SD	n	Mean	SD	n	Mean	SD
Alcohol (units/week)	86	19.3	23.4	83	15.5	19.5	75	18.1	26.8	70	10.8 ^b	18.9	64	4.1	10.8	55	4.4	11.6
Tobacco <i>(cigarettes/week)</i>	73	76.2	48.9	63	76.2	53.3	58	84.6	62.8	54	53.0	52.5	38	52.9	55.5	34	56.3	59.2
Cannabis <i>(joints/week)</i>	68	14.0	16.8	53	19.2	28.6	49	20.9	32.6	47	15.7	25.9	34	13.0	19.6	33	11.3	17.2
Cocaine (grams/week)	56	1.0	3.0	30	0.48	1.1	21	0.6	0.9	20	0.17	0.32	8	0.09	0.08	3	0.03	0.15
MDMA (tabs/week)	54	2.2	3.9	32	1.6	2.6	18	2.5	3.6	19	1.2	1.8	2	1.0	1.36	1	0.16	-
Opiates ^a (<i>units/week</i>)	28	2.4	7.9	8	6.8	14.4	4	6.1	9.9	6	4.7	5.9	3	0.6	0.7	3	0.4	0.5
Crack cocaine (crystals/week)	16	15.4	36	9	14.6	23.5	8	7.9	11.8	6	8.1	13.3	5	1.2	1.7	2	2.1	2.7
Tranquilisers <i>(tabs/week)</i>	28	1.2	2.9	13	0.53	0.84	2	4.5	6.3	3	15.9 ^b	17.7	4	1.4	2.4	3	1.9	2.7
Amphetamines (tabs/week)	55	1.2	2.5	12	0.8	1.3	3	1.1	0.9	5	0.1	0.1	0	-	-	0	_	-
Mushrooms (number/week)	35	3.8	6.4	8	4.7	6.9	1	0.2	-	3	0.4	0.5	0	-	-	0	_	-
LSD (tabs/week)	36	0.42	0.79	5	0.14	0.06	1	0.25	-	2	0.1	0.02	0	-	-	0	-	-
Ketamine (tabs/week)	16	0.33	0.43	3	0.26	0.15	1	7.0	-	0	-	-	1	0.08	-	0	-	-

^aUnits refer to an equivalent amount of grams, millilitres, injections and lines.

^bNote one woman reported taking 35 tranquilisers a week.

Total N=86 Drug used		% of users w	% of users who also used									
	Ν	Alcohol	Tobacco	Cannabis	Cocaine	MDMA						
Lifetime												
Cannabis	68	100%	100%	-	81%	76%						
Cocaine	56	100%	100%	98%	-	91%						
MDMA	54	100%	100%	96%	94%	-						
Year before												
Cannabis	53	98%	100%	-	45%	47%						
Cocaine	30	97%	100%	80%	-	77%						
MDMA	32	97%	100%	78%	72%	-						
1st trimester												
Cannabis	47	87%	79%	-	27%	25%						
Cocaine	20	90%	90%	65%	-	55%						
MDMA	19	95%	84%	63%	58%	-						

Table 3. Patterns of polydrug use over lifetime, the year before pregnancy and during the first trimester

the three most frequently used illegal drugs (cannabis, MDMA and powder cocaine) plus alcohol and tobacco and also compared the average levels² of usage to that reported in the year prior to pregnancy (see Figure 1). We converted the data to percentages in order to be able to directly compare the profiles of usage across drugs and we report relative levels only for those who continued to use the drug.

As can be seen in Figure 1(a), for cocaine and MDMA the number of users and the level of use during pregnancy fell substantially after the first two trimesters. In contrast, the majority of participants who used alcohol in the year before pregnancy continued using it during pregnancy, but at significantly reduced levels. In the first trimester 28 participants reported using no illicit drugs, but even among these women, 10 used tobacco and 19 drank alcohol, with eight both drinking and smoking. Figure 1(B) shows that levels of use of alcohol fell (from around 16 units a week³) to around 60% of this level in the first trimester and then to around 25% in the final two semesters (around four units a week). The majority of tobacco users also continued to smoke during pregnancy. Tobacco users, however, showed a lesser reduction in levels of use than for alcohol, from a year-before average of 77 cigarettes a week to a fairly constant 50-60% level of use through all three trimesters (around 50 cigarettes a week). A similar pattern was also found for use of cannabis, with 60% of users continuing to use upwards of 10 joints a week throughout pregnancy, which was around 60-70% of the level in the year before. Twenty-seven participants used one illicit drug in the first trimester and for the majority (22 of 27) this drug was cannabis. Seventeen of these 27 participants

also smoked and 23 drank alcohol, with 15 doing both. Fourteen participants used two drugs (with 10 also drinking and smoking). Twelve participants used three drugs, and five reported using four drugs (14 of these 17 also drank and smoked tobacco). Almost all those who used recreational drugs in pregnancy used cannabis.

Finally we looked at the levels of use of those 55 women who continued to drink throughout pregnancy, the 34 who used tobacco into the third trimester and the 33 who used cannabis, to see if for these chronic users there were reductions in their use across the three trimesters, and when comparing the first trimester to their reported lifetime use. Related t-tests showed significant reductions in use from lifetime to the first trimester in alcohol use (related-t = 4.3, df = 54, p < 0.001), and in tobacco use (related-t = 3.6, df = 33, p = .005), but not in cannabis use (related-t = 0.49, df = 32, ns). From the first to second trimesters there was a significant reduction in cannabis use (related-t = 2.3, df = 32, p < 0.05) and alcohol use (related-t=2.8, df = 54, p < 0.01), but not in tobacco use (related-t = 1.3, df = 33, ns). From the second to third trimesters there were no significant further reductions in levels of smoking, drinking, or cannabis use for these chronic users (related-t tests ns).

An additional issue of interest is whether those women who continue to use drugs into the third trimester are also those who were high users in the first place. We explored this association by dividing women on the basis of reported use in the year before pregnancy into high and low users. This was done on the basis of the number of drugs reported to have been used. This was considered a conservative approach as it was not based on assumptions regarding distributions. Those women who reported taking three or more recreational drugs (not including alcohol and tobacco) in the year before pregnancy were classified as high users. Thirty-three women fell into this category. We examined the data to see if these women were more likely to be using any drugs in the final trimester, compared to the remaining women. Of these 33 women, 54.5% (n = 18) were still taking at least one drug in the third trimester. This compared to 34% (also n = 18) of the low-use women (there being a total of 36 women who took at least one drug in the third trimester). Although this is

²Table 2 reports the average use per week during the period specified. This was calculated by dividing the total estimated by the participants during the period by the number of weeks in that period. Thus, to gain an idea of the total average amount of exposure to drugs in each trimester of pregnancy then these means should be multiplied by 13 weeks.

³A unit is a standard measure used in publicising alcohol use in UK health advice. It corresponds to around 10 ml of pure alcohol, which is estimated to be contained in half a pint of beer, one small glass of wine or one small 25 ml measure of spirits.




Figure 1. Showing (A) number of continuing drug users across the three trimesters as a proportion of those using the year before and (B) the level of use compared to the average reported use in the preceding year.

suggestive that high lifetime use means women are more likely to continue use of drugs into the third trimester, this association was not quite significant (Chi-squared = 3.54, p = 0.06).

Discussion

This study is the only UK prospective study to date to report in detail and longitudinally the drug use of 'recreational' drug-using women prior to and during pregnancy. The first issue to note was the difficulty we had in recruiting large numbers of participants into the study via hospital midwives. This was a limitation of the study. We speculate that one reason for this may be that, in the UK, women are uncomfortable with revealing their use to midwives, and other prenatal and postnatal carers, for fear of prejudicing their treatment. More studies are required to establish the reasons underlying this reluctance to participate in this type of study. Certainly future studies in the UK will need to address this issue.

The women who took part in our study had a history of using many 'recreational' drugs, having used, on average, at least four different illicit drugs in their lifetime. We advertised explicitly for 'recreational' drug users, yet within the recruited sample were a small sub-sample of potentially dependent opiate users. The majority of the women drank alcohol and smoked tobacco. Of concern was that for most drug users smoking was maintained throughout pregnancy, with women on average smoking in excess of 50 cigarettes a week. On the other hand, alcohol drinking in drug-using women showed a clear reduction after the first trimester, to levels consistent with the maximum safe level recommended by UK government health advice (Directgov, 2007), suggesting that some health messages may be impacting on the behaviour of these women.

While many women reported using amphetamines, mushrooms, tranquilisers, LSD and ketamine at some point in their lifetimes, few reported having used these in the month and year prior to pregnancy, and the use of these drugs during pregnancy was infrequent. However, concerning the two most common 'club drugs', MDMA and cocaine, the majority of women were using these in the year before pregnancy and many continued use in the month prior to pregnancy and into the first trimester⁴. Levels then decreased markedly in

⁴Note that those women who continued using powder cocaine did not show higher levels of drug dependency.

the second and third trimesters. This may reflect a reduction in the attractions of 'clubbing', and associated drug use, in pregnant women. Of particular concern, however, was that many women continued using cannabis. The majority of women reported using cannabis prior to pregnancy, and while there was a reduction in the number of users and levels of use into pregnancy, this reduction was proportionately far less than with the other illicit drugs, with a large sub-group (n=33; 38%) of the pregnant women continuing to smoke, on average, 11 joints a week even into the third trimester.

One can speculate on the possible reasons for continued cannabis use. One possibility is that because cannabis is often perceived as a 'soft drug', it is wrongly assumed by recreational drug-using women to be low risk compared to other legal and illegal substances (Pearson and Shiner, 2002). With cannabis downgraded from a Class B to a Class C drug in the UK in January 2004, this may contribute to the perception that cannabis has less of an effect on the health of adults and children than other 'hard' drugs and alcohol. In the wider population, although there has been a recent decline in usage, overall levels of cannabis use have increased significantly over the last decade, despite health warnings, and this lack of concern over potential negative effects may be continued into pregnancy. Further, as cannabis has not been widely featured as a target for pregnancy education campaigns in the UK, women may feel it is relatively safe to continue using it compared to other drugs. While data from studies in North America and the UK suggest that cannabis can have significant long-term negative effects on both the mother and foetus (Fried and Smith, 2001; Huizink and Mulder, 2006), this information may not be getting through to pregnant women.

However, more work is required with larger samples to determine precisely why recreational drug-using women continue using cannabis and tobacco in pregnancy while reducing the use of alcohol and other recreational drugs. The maintenance of cannabis use may simply be because of the strongly addictive nature of tobacco when taken alone and in joints. Further studies are required to explore the perceptions of risks in pregnant women with histories of recreational drug use and to compare these with the general population. These studies also need to explore the many social, environmental and developmental factors that determine why women continue to use drugs into late pregnancy.

The data revealed considerable polydrug use both in lifetime and pregnancy, with many women having used a combination of alcohol, tobacco, cannabis and in some cases a variety of stimulants and other psychoactive substances. While we are not able to be sure of the timing of co-occurrence of the drugs, which would only be possible using detailed daily diary methods, the data confirm that infants of pregnant drug users in the UK are likely to be exposed in-utero to a multitude of drugs and that single dose effects are likely to be rare. Of particular concern is how the effects of drugs may be multiplied when combined (see, for example, Ben Hamida et al., 2008). Our sample suggests that, in the UK, researchers and practitioners should be particularly concerned with the multiplied effects, throughout pregnancy, of cannabis combined with tobacco and alcohol consumption. There have been proposals (see, for example, Hingson et al., 1982) that combining high

levels of cannabis, tobacco and alcohol may make infants more susceptible to Foetal Alcohol Syndrome (FAS). Future animal studies need to pay particular attention to these potential dose and drug combinations when developing models of the teratological effects of recreational substances on the brain and behaviour.

Our data show that the women report reducing their levels of many club and party drugs leading up to pregnancy and once they know they are pregnant. While it is recognised that these data are based on self-reports from a self-selected sample, the data indicate that many recreational drug-using women are likely to continue to use cannabis throughout their pregnancy in combination with alcohol and tobacco, even though they may stop using other drugs. While the validity of these reports will need to be confirmed with forensic measures, such as hair analysis, the reported patterns of lifetime pre-pregnancy use of our recreational drug-using women were in-line with those reported by other recreational drug users in other studies (see Milani et al., 2004; Parrott et al., 2001; Scholey et al., 2004) and we have no reason to suspect systematic over- or under-reporting.

This pattern of use represents a potentially large risk to the well-being of women and their babies and the concern is that this may be more widespread amongst pregnant women than is presently realised and could be responsible for detrimental long-term developmental outcomes in children, the causes of which are currently unattributable. We will be reporting on the outcomes of the infants born to these mothers in future papers. Further studies with larger samples are required to explore the associations between the continued use of drugs by women in pregnancy and common risk factors, such as relationship status, employment, income, ethnicity and levels of stress (Havens et al., 2009).

Acknowledgments

We thank the women and their babies for their continuing involvement in the study. This study was funded by the National Institute of Drug Abuse (NIH, US), grant number DA14910.

References

- Ben Hamida S, Plute E, Cosquer B, Kelche C, Jones BC, Cassel JC (2008) Interactions between ethanol and cocaine, amphetamine, or MDMA in the rat: thermoregulatory and locomotor effects. *Psychopharmacology* 197: 67–82.
- de Win M.M.L, Reneman L, Reitsma J.B, den Heeten G.J, Booij J, van den Brink W (2004) Mood disorders and serotonin transporter density in ecstasy users - the influence of long-term abstention, dose, and gender. *Psychopharmacology* 173(3-4): 376–382.
- Directgov (2007) UK Government On-line Advice on Alcohol use in Pregnancy. Available at: http://www.direct.gov.uk/en/Parents/ HavingABaby/HealthInPregnancy/DG_171342.
- Drug Abuse Warning Network (DAWN) report. (2000) *Club Drugs*. Rockville, MD: USA Department of Health and Human Services.
- EMCDDA: European Monitoring Centre for Drugs and Drugs addiction (2005). Available at: http://www.emcdda.europa.eu/
- Fergusson DM, Horwood LJ, Northstone K (2002) Maternal use of cannabis and pregnancy outcome. *Bjog–Int J Obstet Gy* 109: 21–27.
- Fried PA, Smith AM (2001) A literature review of the consequences of prenatal marihuana exposure: an emerging theme of a

deficiency in aspects of executive function. *Neurotoxicol Teratol* 23: 1–11.

- Gavin DR, Ross HE, Skinner HA (1989) Diagnostic validity of the Drug Abuse Screening test in the assessment of DSM-III drug disorders. *Brit J Addict* 84: 301–307.
- Havens JR, Simmons LA, Shannon LM, Hausen WF (2009) Factors associated with substance use during pregnancy: results from a national sample. *Drug Alcohol Depen* 99: 89–95.
- Hingson R, Alpert JJ, Day N, et al. (1982) Effects of maternal drinking and marihuana use on foetal growth and development. *Pediatrics* 70: 539–546.
- Huizink AJ, Mulder EJH (2006) Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring. *Neurosci Biobehav R* 30: 24–41.
- Johnston LD, O'Malley PM, Bachman JG (2001) Monitoring the Future: National Results on Adolescent Drug Use. Washington, DC: National Institute on Drug Abuse, US Department of Health and Human Services.
- Lamers C.T.J, Bechara A, Rizzo M, Ramaekers J.G (2006) Cognitive function and mood in MDMA/THC users, THC users and nondrug using controls. J Psychopharmacol 20(2): 302–311.
- MacInnes N, Handley S.L, Harding G.F.A (2001) Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol 15(3): 181–186.
- McElhatton P, Hedgely C, Thomas S (2004) Congenital anomalies after prenatal ecstasy exposure. In: *Proceedings of the British Pharmacological Society*. Claremont Place, Newcastle, UK: National Teratology Information Service (NTIS) RDTC.
- Milani R, Parrott AC, Turner JJD, Fox HC (2004) Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users. *Addict Behav* 29: 965–971.
- Milani RM, Parrott AC, Schifano F, et al. (2005) Pattern of cannabis use in ecstasy polydrug users: Moderate cannabis use may compensate for self-rated aggression and somatic symptoms. *Hum Psychopharm Clin* 20(4): 249–261.
- Milani R, Turner JJD, Parrott AC, Parmar R (2000) Recreational drug use and psychobiological problems, collaborative UK/Italy study (5): Ecstasy (MDMA) polydrug findings. *J Psychopharmacol* 14(3): A15–A15.
- Nicolas, Nicholas S, Kershaw C, Walker A (2007) BCS: British Crime Survey. UK Government: Home Office.
- Parrott AC (2004) MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. *Neuropsychobiology* 50: 329–335.
- Parrott AC (2006) MDMA in humans: factors which influence the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bio-energetic stress. J Psychopharmacol 20: 147–163.

- Parrott AC, Sisk E, Turner J (2000) Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. *Drug and Alcohol Dependence* 60: 105–110.
- Parrott AC, Milani R, Parmar R, Turner JJD (2001) Ecstasy polydrug users and other recreational drug users in Britain and Italy: Psychiatric symptoms and psychobiological problems. *Psychopharmacology* 159: 77–82.
- Pearson G, Shiner M (2002) Rethinking the generation gap: attitudes to illicit drug among young people and adults. *Criminal Justice* 2: 71–86.
- Piper BJ (2007) A developmental comparison of the neurobehavioral effects of ecstasy (MDMA). *Neurotoxicol Teratol* 29: 288–300.
- Reay JL, Hamilton C, Kennedy DO, Scholey AB (2006) MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes. J Psychopharmacol 20: 385–388.
- Rendell PG, Gray TJ, Henry JD, Tolan A (2007) Prospective memory impairment in 'ecstasy' (MDMA) users. *Psychopharmacology* 194: 497–504.
- Rodgers J (2000) Cognitive performance amongst recreational users of 'ecstasy'. *Psychopharmacology* 151: 19–24.
- Scholey AB, Parrott AC, Buchanan T, Heffernan T, Ling J, Rodgers J (2004) Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: A WWW study. *Addict Behav* 29: 743–752.
- Singer LT, Arendt R, Minnes S, et al. (2002) Cognitive and motor outcomes of cocaine-exposed infants. J Amer Med Assoc 287: 1952–1960.
- Singer LT, Linares TJ, Ntiri S, Henry R, Minnes S (2004a) Psychosocial profiles of older adolescent ecstasy users in the United States. *Alcohol and Drug Dependence* 74: 245–252.
- Singer LT, Minnes S, Arendt RE, et al. (2004b) Cognitive outcomes of preschool children with prenatal cocaine exposure. J Amer Med Assoc 291: 2448–2456.
- Skelton MR, Williams MT, Vorhees CV (2008) Developmental effects of 3,4-methylenedioxymethamphetamine: A review. *Behav Pharmacol* 19: 91–111.
- Yacoubian GS, Wish ED (2006) Exploring the validity of selfreported ecstasy use among club rave attendees. J Psychoactive Drugs 38: 31–34.
- Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, et al. (2006) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 20(2): 211–225.
- Yacoubian GS, Boyle C, Harding CA, Loftus EA (2003) It's a rave new world: Estimating the prevalence and perceived harm of ecstasy and other drug use among club rave attendees. J Drug Educ 33: 187–196.